calfactant (infasurf) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Calfactant, also known as Infasurf, is an intratracheal suspension derived from the natural surfactant in calf lungs. It is used in premature infants with lung surfactant deficiency that causes infant respiratory distress syndrome (IRDS).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$57.9067 - $65.5967
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bovactant | calfactant | calf lung surfactant extract (clse) | infasurf

Organizations (20)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (2)


 

Respiratory Distress Syndrome

Respiratory Distress Syndrome, Newborn

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Acute Lung Injury (Phase 2/Phase 3)

Bronchiolitis (Phase 1)

Bronchopulmonary Dysplasia (Phase 3)

Intubation (Phase 3)

Perinatal Death (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn ()

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue